Audentes Therapeutics, Inc.
If you purchased Audentes Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
AUDENTES MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF AUDENTES THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – BOLD
December 2, 2019.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Audentes Therapeutics, Inc. (NASDAQ: BOLD) to Astellas Pharma Inc. (“Astellas”) for $60.00 per share is fair to Audentes shareholders. On behalf of Audentes shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The Audentes merger investigation concerns whether Audentes and members of its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Audentes shareholders; (2) determine whether Astellas is underpaying for Audentes; and (3) disclose all material information necessary for Audentes shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.